In this study, we show that interfering with the splicing machinery results in activation of the tumour-suppressor p53. The spliceosome was targeted by small interfering RNA-mediated knockdown of proteins associated with different small nuclear ribonucleoprotein complexes and by using the small-molecule splicing modulator TG003. These interventions cause: the accumulation of p53, an increase in p53 transcriptional activity and can result in p53-dependent G 1 cell cycle arrest. Mdm2 and MdmX are two key repressors of p53. We show that a decrease in MdmX protein level contributes to p53 activation in response to targeting the spliceosome. Interfering with the spliceosome also causes an increase in the rate of degradation of Mdm2. Alterations in splicing are linked with tumour development. There are frequently global changes in splicing in cancer. Our study suggests that p53 activation could participate in protection against potential tumour-promoting defects in the spliceosome. A number of known p53-activating agents affect the splicing machinery and this could contribute to their ability to upregulate p53. Preclinical studies indicate that tumours can be more sensitive than normal cells to small-molecule spliceosome inhibitors. Activation of p53 could influence the selective anti-tumour activity of this therapeutic approach.
INTRODUCTION
p53 is a short-lived protein in non-stressed cells. p53 rapidly accumulates in response to a number of stresses and its transcriptional activity is increased. This prevents abnormalities, which could lead to cancer being passed on to the daughter cells. Around 50% of the human cancers contain an inactivating mutation in the p53 gene. In the remaining tumours that express wild-type p53, its function is attenuated by other mechanisms including overexpression of repressors or loss of p14ARF. p53 activation using non-genotoxic agents that bypass or overcome these defects in the p53 pathway is a therapeutic approach for tumours expressing wild-type p53. 1, 2 Mdm2 and MdmX are important repressors of p53. 3 --6 Both proteins can inhibit p53 transcriptional activity by binding to its transactivation domain. Mdm2 is also an E3 ligase that promotes the ubiquitination of p53, leading to its degradation by the proteasome. MdmX is structurally similar to Mdm2, however, MdmX alone is not an E3 ubiquitin ligase. Although Mdm2 and MdmX can form a heterodimer that can promote the ubiquitination of p53, under most circumstances suppression of endogenous MdmX does not result in an increase in p53 protein levels. 7 Both Mdm2 and MdmX are subjected to ubiquitination and proteasomal degradation, and stress-dependent destabilisation of Mdm2 and MdmX participates in the activation of p53. 8 --10 Splicing involves the removal of introns from pre-mRNA and the joining of exons. This occurs both co and posttranscriptionally. Splicing is catalysed by the spliceosome, which consists of small nuclear ribonucleoprotein (snRNP) particles: the U1, U2, U4, U5 and U6 snRNPs, which are recruited sequentially to the splice site. Each snRNP contains a unique protein-associated RNA.
11 --13 The spliceosome contains over 150 different proteins. 14 The U1 snRNP interacts with the 5 0 splice site and the U2 snRNP associates with the branch point forming the pre-spliceosome and this is followed by the recruitment of the pre-formed U4/U6.U5 tri-snRNP. After dissociation of the U1 and U4 snRNPs, a complex of the U2, U5 and U6 snRNPs catalyses two transesterification reactions leading to excision of the intron and ligation of the 5 0 and 3 0 exons. At least 95% of human genes undergo alternative splicing. 15, 16 Alternative splicing is a highly regulated process that produces multiple mRNA variants from a single pre-mRNA and consequently makes a major contribution to genetic diversity. This also influences gene expression by removing or inserting regulatory elements controlling translation, mRNA stability or localisation. 17 --19 Aberrant splicing occurs in cancers. 20 --22 There are alterations in the splicing of specific genes, which are associated with tumorigenesis. In addition, there are frequent widespread alterations in splicing, which could contribute to tumour development. This has been linked to changes in spliceosomal components or regulators, many of which are involved in constitutive splicing. 23 --26 General splicing defects may also result from the inability of the splicing machinery to cope with the high levels of transcription in tumours. Small-molecule inhibitors of the spliceosome, which display selective anti-tumour activity, have been described. Pladienolides and spliceostatin A are natural compounds with anti-tumour activity that bind the splicing factor (SF) 3b complex, which is a core component of the U2 snRNP. 27, 28 The mechanisms underlying their selective effects on tumours remain to be defined.
In this study, we show that disruption of the splicing machinery by small interfering RNA (siRNA)-mediated knockdown of multiple spliceosome-associated proteins or using the small-molecule splicing modulator TG003 increases the protein level and transcriptional activity of p53. Targeting the spliceosome causes a p53-dependent accumulation of HCT116 cells in the G 1 phase of the cell cycle. Our data indicate that downregulation of MdmX contributes to the p53 activation that results from interference with the splicing machinery.
RESULTS
Pre-mRNA processing factor (Prpf) 8 and ubiquitin-like (UBL) 5 knockdown activates p53 Two of the hits from siRNA screens that we carried out to identify regulators of p53 were Prpf8 and UBL5 (data not shown). These proteins are involved in splicing of pre-mRNA. Prpf8 is a component of the U5 snRNP and occupies a central position in the catalytic core of the spliceosome. 14, 29 Prpf8 binds multiple key participants in the splicing reaction and can influence splice site selection. UBL5 is involved in the recruitment of at least one essential protein to the U4/U6.U5 tri-snRNP splicing complex. 30 To validate that p53 activation is a genuine consequence of Prpf8 and UBL5 knockdown, A375 melanoma cells stably expressing a p53-responsive reporter construct (RGCDFos-LacZ) were transfected with three individual siRNA complementary to different sequences in their mRNA. Because of the lack of effective antibodies for UBL5, the level of its knockdown was monitored for this and subsequent experiments by reverse transcription quantitative PCR (qPCR) (Supplementary Figure 1) . Knockdown of Prpf8 or UBL5 caused accumulation of p53, elevated p53-responsive transcriptional reporter activity and an increase in the mRNA and protein levels of the p53-target genes Mdm2 and p21 (Figure 1 ). In contrast, MdmX protein expression decreased after their suppression. There was a reduction in MdmX mRNA level, particularly following knockdown of Prpf8, which could contribute to the observed decrease in MdmX protein levels.
To determine whether the effects of Prpf8 and UBL5 suppression are p53-dependent, A375 cells were co-transfected with Prpf8 or UBL5 siRNA and two siRNA, which target all the established p53 mRNA splice variants. Knockdown of p53 attenuated the increases in p53-responsive reporter activity and in the protein and mRNA levels of p21 and Mdm2 observed following knockdown of Prpf8 or UBL5 (Figure 2 ). These data indicate that Prpf8 and UBL5 knockdown increases p53 transcriptional activity.
In A375 cells, Prpf8 or UBL5 knockdown reduced the number of nuclear speckles detected by immunofluorescent staining for the SF SC35, but the remaining speckles increased in size and intensity (Supplementary Figure 2) . Such changes in SC35-staining speckles are used as a marker for disruption of the splicing machinery. 27, 28 This confirms that knockdown of these proteins was sufficient to have an impact on the splicing machinery. Suppression of Prpf8 or UBL5 also selectively altered the splicing events examined, indicating that the level of knockdown was sufficient to influence splicing (Supplementary Figure 3) . This selectivity could be due to variations in the nature of splicing sites and associated regulatory sequences, which influence the functional interaction with the splicing machinery. Partial suppression of the spliceosome through knockdown of components of the splicing machinery could influence competition between alternative splice sites for the splicing machinery. This competition is important in splice site selection. 31 Targeting the spliceosome in multiple ways activates p53 The effects of Prpf8 or UBL5 suppression suggest that targeting the RNA splicing machinery can activate p53. To determine the generality of this, four additional proteins involved in different subcomplexes of the spliceosome were knocked down. The proteins targeted were U1-70K, SF3b1, ubiquitin-specific peptidase (USP) 39 and Prpf31. U1-70K is a component of the U1 snRNP and is important for stabilisation of the U1 snRNP structure, the recognition of the 5 0 splice site and initiation of spliceosome assembly. 32 --34 SF3b1 is a subunit of the SF3b subcomplex, which is a component of the U2 snRNP. 35 This subcomplex is involved in the recognition of the pre-messenger RNA branch site and has an essential role during assembly of the pre-spliceosome. It is the target of spliceostatin A and pladienolide. SF3b1 stabilises the structure of the U2 snRNP and forms a scaffold facilitating protein --protein and protein --RNA interactions during splicing.
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Prpf31 binds to the U5 snRNP protein Prpf6 to connect the U4/U6 with the U5 snRNP. 37, 38 USP39 is required for recruitment of the U4/U6.U5 tri-snRNP to the pre-spliceosome.
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A375 cells were transfected with multiple siRNA complementary to different sequences within U1-70K, SF3b1, USP39 and Prpf31. Consistent with disruption of the splicing machinery, knockdown of these proteins altered the pattern of SC35-positive nuclear speckles (Supplementary Figure 2) and had a selective effect on the expression of alternatively spliced forms of the mRNA analysed (Supplementary Figure 3) . It was recently reported that only a minority of the splicing events detected using a splicingsensitive microarray are influenced by siRNA-mediated knockdown of SF3b1. 39 It was suggested that selectivity is because of variations in the interaction of the U2 snRNP with different intronic RNA sequences.
Knockdown of U1-70K, SF3b1, USP39 and Prpf31 resulted in elevated p53 and p21 protein levels, p53-responsive transcriptional reporter activity and mRNA expression of Mdm2 and p21 ( Figure 3 ). For all the components of the splicing machinery targeted, p53 activation was associated with a decrease in MdmX protein expression. In all cases, except for U1-70K knockdown, MdmX mRNA levels were reduced. Full-length Mdm2 protein expression was reduced by suppression of SF3b1 but not by knockdown of the other SFs.
To further assess the link between p53 activation and interfering with the splicing machinery, A375 cells were treated with TG003. This is a small-molecule splicing modulator that inhibits Cdc2-like kinases. 40 These kinases participate in the regulatory phosphorylation of serine-arginine-rich proteins (SR proteins). SR proteins influence multiple steps in constitutive and alternative splicing, including splice site recognition, recruitment of the U4/U6.U5 tri-snRNP and spliceosome-mediated catalysis. 41 Treatment of cells with TG003 altered SC35-staining nuclear speckles, confirming that this drug affects the splicing machinery (Supplementary Figure 2) . In addition, it had a selective effect on mRNA splicing (Supplementary Figure 3) . TG003 increased p53, Mdm2 and p21 protein expression, whereas MdmX protein levels were reduced (Figure 4a ). It also increased mRNA expression of p21 and Mdm2, whereas MdmX mRNA levels were reduced ( Figure 4c ). TG009 is a structural analogue of TG003 that is a 1000-fold less potent inhibitor of Cdc2-like kinases. 40 TG003, but not TG009, increased p53-responsive reporter activity in a dosedependent manner (Figure 4b ). To determine whether these effects are p53-dependent, A375 cells were transfected with two different siRNAs targeting p53 prior to incubation with TG003. No increase in p21 protein level was observed in cells in which p53 was knocked down (Figure 4d ). Both Mdm2 and MdmX protein levels were reduced by p53 knockdown, and TG003 caused a further decrease in the protein expression of these two repressors. The TG003-dependent increase in p53-reponsive reporter activity was also attenuated by knockdown of p53 ( Figure 4e ).
To further investigate the p53-dependence of the effects of targeting the splicing machinery, we used HCT116 cells that express wild-type p53 (HCT116-p53 þ / þ ) and a derivative lacking full-length p53 (HCT116-p53
). Reducing the expression of Prpf8 or UBL5, or treatment with TG003 resulted in the accumulation of p53 in HCT116-p53 þ / þ cells ( Figure 5 ). These interventions also caused a p53-dependent increase in p21 protein and Mdm2 mRNA levels. In contrast, downregulation of MdmX protein occurred independently of p53. These data indicate that disrupting the RNA splicing machinery causes an increase in p53 protein level and transcriptional activity. This is associated with a p53-independent decrease in MdmX protein expression.
Inhibition of splicing causes the p53-dependent accumulation of cells in G1
The effect of targeting the spliceosome on the cell cycle and the contribution of p53 to this were investigated. HCT116-p53
À/À cells were transfected with siRNA targeting Prpf8 or UBL5 for 48 h or were treated with TG003 for 24 h and the cell cycle distribution was determined by flow cytometry after BrdU-labelling. In HCT116-p53 þ / þ cells, SF knockdown or TG003 caused an increase in the proportion of cells in G 1 and a decrease in the proportion in S phase ( Figure 5 ). In contrast, in the HCT116-p53 À/À cell line, the percentage of cells in the G 2 /M phase was increased following Prpf8 knockdown or treatment with TG003, whereas no change in the cell cycle distribution was observed p53 can be activated in response to targeting the spliceosome without gross changes in the splicing of Mdm2/MdmX, DNA damage and global inhibition of transcription To investigate the mechanism of p53 activation, we looked at the effects of targeting the splicing machinery on the splicing of MdmX and Mdm2, and markers of DNA damage and general transcription ( Figure 6 ). MdmX and Mdm2 mRNA expression were determined by semiquantitative reverse transcription PCR. As observed using reverse transcription qPCR, the levels of MdmX mRNA were reduced for all of the interventions except for U1-70K knockdown. No shift to alternatively spliced forms of MdmX was detected. In all cases, except for SF3b knockdown, the approaches used to interfere with the splicing machinery did not grossly disrupt splicing of full-length Mdm2. Suppression of SF3b1 reduced the level of full-length Mdm2 mRNA and increased the levels of alternatively spliced mRNA species corresponding to Mdm2-B/Mdm2-alt1 and Mdm2-A1. 42 Consistent with these observations, SF3b knockdown, but not the other interventions used, caused a switch to the expression of alternative protein isoforms of Mdm2 (Supplementary Figure 4) . These data indicate that altered splicing of Mdm2 mRNA is responsible for the decrease in full-length Mdm2 protein levels following SF3b1 knockdown. This is likely to contribute to the p53 activation in response to the suppression of SF3b1.
Phosphorylation of histone H2AX resulting in the formation of gH2AX is commonly used to assess DNA damage. 43 Treatment with TG003 or knockdown of U1-70K, USP39, Prpf31 and UBL5 increased p53 and p21 protein expression and reduced MdmX protein levels without affecting phosphorylation of H2AX. p53 and p21 were accumulated and MdmX protein expression was reduced within 24 h of transfection with siRNA targeting SF3b1 and Prpf8, however, increased gH2AX was only observed 48 h after transfection. These data indicate that DNA-damage is not the cause of p53 activation due to targeting the spliceosome. p53 is accumulated in response to inhibition of RNA polymerase II-dependent transcription. 44 Stalling or arrest of polymerase II during elongation leads to its degradation by the ubiquitin --proteasome system, 45 and Ser2 phosphorylation of the C-terminal domain of the largest subunit of polymerase II (RPB1) is associated with transcriptional elongation. We observed that SF knockdown or treatment with TG003 had no effect on the level of RPB1 or Ser2 phosphorylation of the C-terminal domain ( Figure 6 ). This indicates that under the conditions used in this study, there was no global inhibition of transcription. Consistent with this, it has been reported that in mammalian systems, splicing and splicing inhibition do not alter the rate of transcriptional elongation. 46, 47 Targeting the spliceosome promotes the degradation of Mdm2 and MdmX and stabilises p53 To further investigate how p53 is upregulated due to targeting the spliceosome, we looked at the effect of inhibiting the splicing machinery on the stability of p53, Mdm2 and MdmX. A375 cells were treated with TG003 or transfected with control, SF3b1, UBL5 or Prpf8 siRNA and were incubated with cycloheximide to inhibit protein synthesis for the indicated times before harvesting. Targeting the splicing machinery increased the stability of p53 and caused destabilization of Mdm2 and MdmX (Figure 7 ). This decrease in the stability of the two key regulators of p53 could contribute to the p53 activation as a result of targeting the spliceosome. Downregulation of MdmX participates in p53 activation in response to inhibition of the splicing machinery A decrease in MdmX protein expression was observed following the targeting of the spliceosome by all of the different approaches used in this study. To investigate whether this could participate in p53 activation, A375 cells were transfected with siRNA complementary to different sequences in MdmX (Figures 8a --c) . Knockdown of MdmX increased p21 protein levels and the mRNA levels of the p53-target genes, Mdm2 and p21, and caused a modest increase in p53-responsive reporter activity. No increase in p53 protein levels was detected, consistent with previous studies. 7 The decrease in MdmX protein levels due to interference with the Figure 4 . The small-molecule splicing modulator TG003 downregulates MdmX and activates p53. A375 cells were incubated with the indicated concentration of TG003 for 24 h. TG003: (a) increases p53, Mdm2 and p21 protein levels, but reduces protein expression of MdmX, (b) enhances p53-reporter activity, whereas TG009, a structural analogue, which is a poor inhibitor of Cdc2-like kinases, has no effect and (c) increases Mdm2 P2 and p21 mRNA levels. TG003 acts in a p53-dependent manner. A375 melanoma cells were transfected with control siRNA or siRNA complementary to two different sequences in p53. After 48 h, the A375 cells were treated with 100 mM TG003 for 24 h as indicated. (Figures 8d --f) . Transfection with siRNA targeting MdmX and Prpf8 resulted in a comparable decrease in MdmX protein expression. In HCT166-p53 þ / þ , MdmX or Prpf8 knockdown resulted in similar increases in p21 protein level and Mdm2 mRNA expression. As in A375 cells, no increase in p53 protein level was observed after MdmX knockdown. In HCT166-p53 þ / þ cells, both MdmX and Prpf8 knockdown caused an increase in the percentage of cells in G 1 and a decrease in the proportion of cells in S phase. To further investigate the role of MdmX, a U2OS cell line stably expressing elevated levels of MdmX and a matched U2OS control cell line stably expressing empty vector were used ( Figure 9 ). In control U2OS cells, TG003 treatment or SF knockdown resulted in an increase in p53 protein expression and an increase in the mRNA of Mdm2 and p21. As observed in the other cell lines tested, these interventions decreased MdmX protein expression. In cells expressing elevated MdmX, the increase in p21 and MdmX mRNA expression following incubation with TG003 or SF knockdown was attenuated. These data support a role for MdmX downregulation in p53 activation following targeting of splicing.
DISCUSSION
We show that p53 is activated in response to disrupting the splicing machinery. Knockdown of proteins involved in splicing or treatment with the splicing modulator TG003 causes the accumulation of p53 protein and an increase in p53 transcriptional activity. In HCT116 cells, targeting the spliceosome results in a p53-dependent accumulation of cells in G 1 . Interfering with the spliceosome causes a reduction in MdmX expression, which provides a mechanism for p53 activation. p53 may be involved in protecting cells against potential tumour-promoting alterations in the splicing machinery. In this study, the spliceosome was targeted in multiple ways. Important components of the U1 (U1-70K), U2 (SF3b1) and U5 (Prpf8) snRNPs were knocked down. In addition, proteins were knocked down that are required for U4/U6.U5 tri-snRNP assembly (Prpf31), its association with essential proteins (UBL5) and its recruitment to the pre-spliceosome (USP39). The small-molecule splicing modulator TG003 was also used. This inhibits the phosphorylation of serine-arginine-rich SFs.
All of these interventions result in an increase in p53 protein level and transcriptional activity. This indicates that p53 activation is a general consequence of interfering with the spliceosome. This response could protect cells against potential tumourpromoting defects in the splicing machinery. Alterations in splicing occur in cancer. 20 --22,25,48 This can promote tumour development by giving rise to alternative isoforms of oncogenes and tumour suppressors. Changes in splicing have been Knockdown of U1-70K, USP39, Prpf31 and UBL5, and treatment with TG003 does not affect phosphorylation of H2AX. This indicates that DNA damage is not responsible for the observed activation of p53. Knockdown of spliceosomal proteins and treatment with TG003 did not alter levels of RNA polymerase II (poll II) or Ser2 phosphorylation of the C-terminal domain. This indicates that global inhibition of transcription does not occur under the conditions used. IIo, hyperphosphorylated form of polII; IIa, hypophosphorylated form of polII.
p53 and the spliceosome N Allende-Vega et al associated with higher rates of proliferation, increased cell motility and drug resistance. In addition to changes in splicing due to mutations in particular genes that generate or disrupt splice sites, splicing enhancers or silencers, there are global alterations in splicing in cancers. 23, 49, 50 General splicing disruption is estimated to occur in 50% of cancers. This is associated with altered splicing of key SFs, the majority of which are involved in constitutive splicing. 23 The expression of a number of SFs involved in constitutive and alternative splicing is altered in cancer. 24 --26 General splicing defects in tumours may also be due to the inability of the splicing machinery to cope with high proliferation rates and the associated high levels of transcription. 23 A number of p53-activating stresses affect the spliceosome and splicing. The sensing of defects in the spliceosome by the p53 pathway could contribute to its activation in response to these stresses and facilitate protection against alterations in splicing. Heat shock inhibits splicing through a mechanism that involves interfering with the assembly of the U4/U6.U5 tri-snRNP. 51 Oxidative stress results in defective splicing due to changes in the splicing machinery. 52 5-fluorouracil is incorporated into U2 snRNA, which attenuates splicing. 53 Leptomycin B is a potent activator of p53, which targets the nuclear export factor CRM1. 54 This can indirectly block snRNP nuclear import and can also inhibit CRM1-dependent trafficking of snRNPs within the nucleus. 55 Splicing is altered by DNA damaging agents including UV, cisplatin and mitomycin C. 56 This could be due to DNA damage-induced signalling pathways, which modulate SFs, 57,58 changes in chromatin structure, which alter the accessibility to SFs, 56 and decreases in the rate of transcriptional elongation, which can influence splice site selection. 31, 59 Inhibitors of the spliceosome are under development for use in cancer therapy. Spliceostatin A and pladienolide B are naturally occurring compounds with selective anti-tumour activity. Studies in animal models indicate that there is a therapeutic window, which allows the targeting of tumours without affecting normal cells. Activation of p53 could influence the selective anti-tumour activity of this therapeutic approach.
We have initiated studies to investigate the mechanism of p53 activation following targeting of the spliceosome. Our data indicate that DNA damage and general inhibition of transcription are not the cause of p53 activation. To date, we have been unable to detect changes in alternative splicing of p53, 60, 61 which could account for p53 activation in response to knockdown of spliceosomal proteins (data not shown). A common feature of the disruption of the spliceosome was a reduction in the protein level of MdmX. This was associated with enhanced degradation of MdmX protein and a reduction in MdmX mRNA expression. The decrease in MdmX protein participates in, but cannot fully account for, p53 activation. siRNA-mediated knockdown of MdmX partially recapitulated the effects of targeting the spliceosome on the p53 pathway. Importantly, ectopic expression of MdmX inhibited p53 transcriptional activation in response to targeting the splicing machinery. However, as anticipated, MdmX knockdown did not result in an increase in the level of p53. Targeting the spliceosome caused a decrease in the stability of Mdm2, which could also contribute to the p53 activation. Destabilisation of Mdm2 participates in p53 accumulation and activation in response to other cellular stresses. 8, 10 SF3b1 knockdown, but not the other interventions used, caused a marked alteration in splicing of Mdm2. Two major Mdm2 mRNA species generated following SF3b1 knockdown encode for isoforms of Mdm2 (Mdm2-B/Mdm2-alt1 and Mdm2-A1) that are defective in repressing p53 because they lack most of the N-terminal p53-binding domain. Exon 12 was present in these mRNAs, which encodes for both the zincfinger and RING domains of Mdm2. Such isoforms can activate p53 by interfering with repression by full-length Mdm2. 62 These changes in Mdm2 splicing are likely to contribute to the p53 activation following the suppression of SF3b1. This is of particular interest because spliceostatin A and pladienolide B, which display selective anti-tumour activity, bind the SF3b subcomplex that contains SF3b1. Spliceostatin A inhibits the interaction of SF3b1 with pre-mRNA. 39 The mechanisms leading to the observed effects on MdmX mRNA levels, and Mdm2 and MdmX protein stability remain unclear. An increase in alternatively spliced forms of MdmX that could account for the reduction in normally spliced MdmX mRNA was not detected. However, it remains possible that alterations in splicing of MdmX could generate MdmX RNA species that are degraded by RNA surveillance pathways. 63 There are a number of ways in which defects in the splicing machinery could be sensed and result in the observed effects on Mdm2 and MdmX. There could be a signalling pathway that is triggered in response to defects in spliceosome assembly or through changes in the cellular localisation of spliceosomal components. Sensing of alterations to the splicing machinery could involve the interaction of components of the splicing machinery with Mdm2/MdmX or their regulators. This would be comparable to the events involved in the effects of ribosomal stress on the p53 pathway. There may be a sensing mechanism that is dependent on the rate of splicing. Alternatively, a signal could be generated due to increased levels of improperly spliced RNA. This could include unspliced RNA or splicing intermediates. Changes in the splicing of regulators of Mdm2 and MdmX could also be involved in the observed alterations. Additional studies are required to more fully determine the signalling pathway, leading from spliceosome disruption to p53 activation. This would help to further elucidate the role of the p53 pathway as a sensor of alterations in the splicing machinery.
MATERIALS AND METHODS
Cell culture A375 and U2OS cells were cultured in Dulbecco's modified Eagles medium, HCT116 cells were cultured in McCoy's 5A medium, both supplemented with 10% fetal bovine serum and penicillin/streptomycin. Cells were grown at 37 1C and 5% CO 2 in a humidified atmosphere. The U2OS cell line stably expressing MdmX and the control U20S cell line were provided by Dr Jiandong Chen.
Synthetic siRNA duplexes and transfections All siRNA duplexes used for SF knockdown were Dharmacon ONTARGETplus modified (Thermo Fisher Scientific, Epsom, UK). p53 siRNAs complementary to all known splice forms of p53 were described previously. 64 
b-Galactosidase assay
The assay was performed as described previously. 64 
Western blotting
The primary antibodies used are listed in Supplementary Figure 6 . Cell extracts were lysed into 2 Â SDS sample buffer. Proteins were resolved by SDS --PAGE and transferred to nitrocellulose overnight at 25 mA. Peroxidase-coupled anti-mouse and anti-rabbit secondary antibodies were used at a dilution of 1:10 000 (Jackson ImmunoResearch, Newmarket, UK). Bound antibodies were detected by Amersham enhanced chemiluminescence (GE Healthcare Life Sciences, Little Chalfont, UK) or using Pierce super signal west dura extended duration substrate (Thermo Fisher Scientific, Cramlington, UK).
RNA preparation and PCR
Total RNA was extracted using RNeasy columns (Qiagen, Crawley, UK), reverse transcription was carried out using random primers and qPCR was performed as described previously. 65 The Mdm2 gene has two promoters. One of these is p53-independent (P1) and the other is p53-responsive (P2). Throughout this study, Mdm2 P2 mRNA levels (exon 2 to 3 boundary) were measured by qPCR. For MdmX probes were used for qPCR, which amplify the exon 6 to 7 boundary. For p21, the probes used for qPCR amplify the exon 2 to 3 boundary. These exons contain the entire coding region for classical p21. The primers and probes used for qPCR of p21, the p53-responsive Mdm2-P2 transcript and MdmX are described previously. 66, 67 For semiquantitative PCR, 1 mg of RNA was reverse-transcribed using random primers. One-twentieth of the cDNA was amplified by PCR using the appropriate primers. After 27 cycles of 1 min at 95 1C, 45 s at 57 1C and 1 min at 72 1C, the products were analysed on agarose gels. The major bands were excised and sequenced. Additional primers and probes used for PCR are listed in Supplementary Figure 5 .
Immunofluorescence Cells were seeded on glass slides and transfected with synthetic siRNA duplexes for 24 h or treated with TG003 for 4 h. Cells were fixed with 2% formaldehyde, permeabilized with 0.2% Triton X-100 and incubated with monoclonal anti-SF antibody SC-35 (Sigma, Gillingham, UK) and rabbit polyclonal CM-1 for p53. Alexa Fluor 488 dye-conjugated anti-mouse and Invitrogen alexa fluor 594 dye-conjugated anti-rabbit secondary antibodies were used (Life Technologies Ltd).
Flow cytometry
Flow cytometry analysis of cells was performed as described previously. 66 
